Cargando…

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study

BACKGROUND: Digital healthcare systems data could provide insights into the global prevalence of chronic kidney disease (CKD). We designed the CaReMe CKD study to estimate the prevalence, key clinical adverse outcomes and costs of CKD across 11 countries. METHODS: Individual-level data of a cohort o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sundström, Johan, Bodegard, Johan, Bollmann, Andreas, Vervloet, Marc G., Mark, Patrick B., Karasik, Avraham, Taveira-Gomes, Tiago, Botana, Manuel, Birkeland, Kåre I., Thuresson, Marcus, Jäger, Levy, Sood, Manish M., VanPottelbergh, Gijs, Tangri, Navdeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459126/ https://www.ncbi.nlm.nih.gov/pubmed/36090671 http://dx.doi.org/10.1016/j.lanepe.2022.100438

Ejemplares similares

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
por: Norhammar, Anna, et al.
Publicado: (2023)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
por: Schechter, Meir, et al.
Publicado: (2022)

Conventional Risk Factors Associated With Meaningful Outcomes in Advanced CKD
por: Collister, David, et al.
Publicado: (2018)

Effects of Veverimer in Older Adults With CKD and Metabolic Acidosis
por: Tangri, Navdeep, et al.
Publicado: (2021)

Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
por: Hasvold, Pål, et al.
Publicado: (2015)

Development and External Validation of a Machine Learning Model for Progression of CKD
por: Ferguson, Thomas, et al.
Publicado: (2022)

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
por: Birkeland, Kåre I., et al.
Publicado: (2019)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Metabolic Acidosis and Cardiovascular Disease in CKD
por: Collister, David, et al.
Publicado: (2021)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

Metabolic Acidosis and Adverse Outcomes and Costs in CKD: An Observational Cohort Study
por: Reaven, Nancy L., et al.
Publicado: (2023)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Physical Function in Adults With Metabolic Acidosis and Advanced CKD: Patient Reported Versus Assessed Physical Function
por: Tangri, Navdeep, et al.
Publicado: (2022)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Association of frailty and physical function in patients with non-dialysis CKD: a systematic review
por: Walker, Simon R, et al.
Publicado: (2013)

The Effect of Age on Performance of the Kidney Failure Risk Equation in Advanced CKD
por: Hundemer, Gregory L., et al.
Publicado: (2021)

CaREM1.4 interacts with CaRIN4 to regulate Ralstonia solanacearum tolerance by triggering cell death in pepper
por: Zhang, Yanqin, et al.
Publicado: (2023)

Risk of Kidney Failure, Death, and Cardiovascular Events After Lower Limb Complications in Patients With CKD
por: Li, Kevin, et al.
Publicado: (2020)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Association of Bone Mineral Density With Fractures Across the Spectrum of Chronic Kidney Disease: The Regina CKD-MBD Study
por: Prasad, Bhanu, et al.
Publicado: (2019)

Patient Navigators for CKD and Kidney Failure: A Systematic Review
por: Taha, Ali, et al.
Publicado: (2022)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Initial and Recurrent Hyperkalemia Events in Patients With CKD in Older Adults: A Population-Based Cohort Study
por: Sriperumbuduri, Sriram, et al.
Publicado: (2021)

Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD
por: Tangri, Navdeep, et al.
Publicado: (2022)

Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study
por: Tangri, Navdeep, et al.
Publicado: (2023)

The Kidney Failure Risk Equation Score and CKD Care Delivery Measures: A Cross-sectional Study
por: Ahmed, Salman, et al.
Publicado: (2021)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

A Cost-Minimization Analysis of Nurse-Led Virtual Case Management in Late-Stage CKD
por: Ferguson, Thomas W., et al.
Publicado: (2020)

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
por: Hasvold, L P, et al.
Publicado: (2014)

Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
por: Vervloet, Marc G
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study
por: Grundvold, Irene, et al.
Publicado: (2015)

Metabolic Acidosis is Associated With Acute Kidney Injury in Patients With CKD
por: Zhu, Antonia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fecq0v1ohh9tep8n61hj7rk6qf